Gapping up
In reaction to earnings/guidance:
- PLTR +18.3%, SKYT +9.4%, KULR +6% (Q4 guidance), EMBC +5.5%, BLKB +5%, IRBT +4.4%, CDNS +3.8%, NTB +3.2%, ZTS +3.2%, DENN +3%, KRG +2.7%, CAR +1.8%, GFS +1.6%, PAX +1.5%, ANET +1.4%, OTTR +1.3%, WCC +1.3%, KO +1.2%, IAC +1%, MAR +0.8%
Other news:
- FUSN +20.4% (acquires RadioMedix)
- AMLX +6% (will provide a corporate update including information on the commercial launch of RELYVRIO at upcoming conference)
- GRTS +4.1% (entered into a clinical trial agreement with the National Cancer Institute to evaluate an autologous T cell therapy expressing a T cell receptor targeting mutated KRAS in combination with Gritstone's KRAS-directed vaccine candidate SLATE-KRAS in a Phase 1 study)
- BTAI +3.5% (announces data from Phase 2 trial of BXCL701)
- KALV +3.1% (provides multiple clinical trial and regulatory updates for its lead compound sebetralstat as a potential oral on-demand therapy for HAE attacks)
- MCRB +3% (announces the publication of data from its Phase 3 ECOSPOR IV trial in JAMA Network Open that reinforce previously published results from the Phase 3 ECOSPOR III study on the investigational microbiome therapeutic SER-109 for the prevention of recurrent C. difficile infection)
- USNA +2.3% (CEO transitioning to Executive Chairman; new CEO named)
- SNDL +2% (reducing headcount)
- BCYC +1.8% (Announces Phase I Dose Escalation Results from Ongoing Phase I/II Study of BT8009)
- EQC +1.4% (declares special cash dividend)
- EGY +1.1% (raises dividend; provides operational update)
Analyst comments:
- FIS +1.5% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- PANW +1.3% (initiated with a Buy at Goldman)
- OXY +1.1% (upgraded to Buy from Neutral at Goldman)
- FTNT +0.6% (initiated with a Buy at Goldman)